FINAL RESULTS FOR THE YEAR ENDED 31 MARCH 2025
Incanthera plc (AQSE: INC), the specialist company focused on innovative technologies in dermatology and oncology is pleased to announce its audited results for the year ended 31 March 2025.
Incanthera is dedicated to identifying and commercialising novel therapeutic and cosmetic applications that are based upon uniquely targeted delivery technologies.
Post Balance Sheet Highlights:
- Skin+CELL luxury skincare range launched 11 August 2025 via a dedicated Direct To Consumer (“DTC”) website
Link: www.skinandcell.com
- DTC campaign launched across social media, building into digital and traditional media
- Skin+CELL products available for purchase include face, body and hand, face serum and eye cream
- Proof of concept achieved for Skin+CELL formulation technology, demonstrating protective effects of Skin + CELL against UV-induced damage in human skin cells
Financial Highlights:
- First revenues of Skin+CELL achieved in first weeks of launch
- Institutional fundraise of £508,000 June 2025
- Tight cost controls through lean business model
- Protection of valuable IP across global territories
Simon Ward, Chief Executive Officer, commented:
“I am immensely proud of our Skin+CELL product range, now available to the world-wide market, and achieving sales, following the launch on 11 August via our dedicated DTC website:
www.skinandcell.com
There has been immediate positive feedback from users of our Skin+CELL products, extolling the beneficial impact on their skin tone and appearance and confirming that Skin+CELL will be an integral part of their skin and beauty regimen going forward.
“As the DTC campaign has developed, we have seen good engagement and conversion to sales, increasing in recent weeks. As this gathers further momentum over the next period, we anticipate sales volumes to increase accordingly, and our expectation is to sell the current stock of 100,000 units by 31 March 2026.
“We are also actively exploring additional routes to market to add to the DTC route and are in the active design and development phase of our new range to include SPF concentrations.
“Following on from what has been a truly challenging year, we now look forward with confidence.
“I take this opportunity, on behalf of myself and the team, to thank all our partners, advisors and our very loyal shareholders for their continued unwavering support.”
This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement
For further enquiries:
Incanthera plc:
www.incanthera.com
Tim McCarthy, Chairman
tim.mccarthy@incanthera.com
+44 (0) 7831 675747
Simon Ward, Chief Executive Officer
simon.ward@incanthera.com
+44 (0) 7747 625506
Suzanne Brocks, Head of Communications
suzanne.brocks@incanthera.com
+44 (0) 7776 234600
Aquis Exchange Corporate Adviser:
Cairn Financial Advisers LLP
Jo Turner / Liam Murray
+44 (0) 20 7213 0880
Broker:
Stanford Capital Partners Ltd
Patrick Claridge / Bob Pountney
+44 (0) 20 3650 3650/51
Download release in full